GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenerx Biopharmaceuticals Inc (OTCPK:RGRX) » Definitions » Profitability Rank

Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Profitability Rank : 0 (As of Mar. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Regenerx Biopharmaceuticals Profitability Rank?

Regenerx Biopharmaceuticals has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Regenerx Biopharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2023 was -1,605.26%. As of today, Regenerx Biopharmaceuticals's Piotroski F-Score is 0.


Competitive Comparison of Regenerx Biopharmaceuticals's Profitability Rank

For the Biotechnology subindustry, Regenerx Biopharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenerx Biopharmaceuticals's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Regenerx Biopharmaceuticals's Profitability Rank falls into.



Regenerx Biopharmaceuticals Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Regenerx Biopharmaceuticals has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Regenerx Biopharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2023 ) / Revenue (Q: Mar. 2023 )
=-0.305 / 0.019
=-1,605.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Regenerx Biopharmaceuticals has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Regenerx Biopharmaceuticals Profitability Rank Related Terms

Thank you for viewing the detailed overview of Regenerx Biopharmaceuticals's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Executives
Aptafin S P A other: Member of 10% owner group VIALE SHAKESPEARE 47, ROME L6 00144
Alessandro Noseda director C/O 15245 SHADY GROVE ROAD, SUITE 470, ROCKVILLE MD 20850
S.a. Sinaf 10 percent owner 26 BOULEVARD ROYAL, LUXEMBOURG N4 L-2449
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Francesca Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Preta Martina Cavazza 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Mauro Bove director C/O REGENERX BIOPHARMACEUTICALS, INC., 3 BETHESDA METRO CENTER - SUITE 630, BETHESDA MD 20814
R Don Elsey director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
J J Finkelstein director
Joseph C Mcnay director 3 BETHESDA METRO CENTER STE 700, C/O REGENERX BIOPHARMACEUTICALS INC, BETHESDA MD 20814
Allan L Goldstein director
Dane R Saglio officer: Chief Financial Officer
Aria Digital 10 percent owner 22ND FL, PARKVIEW TOWER,, 248 JUNGJAIL-RO, BUNDANG-GU,, SEONGNAM-SI, GYEONGGI-DO M4 463-863